SCHEMBL1734572

SCHEMBL1734572

CCN(CCO)c1nc(C(N)=O)cc(-c2cccc(OC)c2)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.61
ADORA1 P30542 4/20 0.43
ADORA2A P29274 3/20 0.43
PARP1 P09874 1/20 0.41
ADORA3 P0DMS8 2/20 0.41
ADORA2B P29275 2/20 0.41
IKBKB O14920 1/20 0.41
TRPV1 Q8NER1 2/20 0.41
SCN9A Q15858 1/20 0.41
IRAK4 Q9NWZ3 1/20 0.39
ALDH1A1 P00352 4/20 0.39
HPGD P15428 4/20 0.39
HSD17B10 Q99714 2/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1734461 0.92 KDM4E (0.72) KDM4EADORA1ADORA2APARP1ADORA3
SCHEMBL1733611 0.86 KDM4E (0.83) KDM4EADORA1ADORA2AADORA3ADORA2B
SCHEMBL1734527 0.83 KDM4E (0.70) KDM4ESCN9AALDH1A1HPGDLMNA
SCHEMBL1733546 0.82 KDM4E (0.52) KDM4EADORA1ADORA2APARP1ADORA3
SCHEMBL1733483 0.81 KDM4E (0.51) KDM4EADORA1ADORA2AADORA3ADORA2B
SCHEMBL1733468 0.80 KDM4E (0.57) KDM4EADORA1ADORA2APARP1ADORA3
SCHEMBL1734592 0.80 KDM4E (0.66) KDM4EADORA1ADORA2ASCN9AIRAK4
SCHEMBL1734177 0.80 KDM4E (0.73) KDM4EPARP1ADORA3ADORA2BALDH1A1
SCHEMBL1734575 0.78 KDM4E (0.70) KDM4EALDH1A1HPGDMAPTTP53
SCHEMBL1735802 0.78 KDM4E (0.73) KDM4EADORA2APARP1IKBKBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US claimed
EP-1891018-B1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2011-11-16 EP claimed
WO-2011131686-A1 A THERMALLY CONTROLLED ASSEMBLY NAPATECH A/S (DK) 2011-10-27 WO claimed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US claimed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105833-A1 Modulators of ATP-binding cassette transporters ABCC4, CFTR, ABCC2 KDM4E 3910/4885ADORA1 142/4885ADORA2A 161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.